ImmunityBio Management
Management criteria checks 4/4
ImmunityBio's CEO is Rich Adcock, appointed in Oct 2020, has a tenure of 3.58 years. total yearly compensation is $1.16M, comprised of 68.8% salary and 31.2% bonuses, including company stock and options. directly owns 0.035% of the company’s shares, worth €1.26M. The average tenure of the management team and the board of directors is 3.6 years and 4.2 years respectively.
Key information
Rich Adcock
Chief executive officer
US$1.2m
Total compensation
CEO salary percentage | 68.8% |
CEO tenure | 4yrs |
CEO ownership | 0.03% |
Management average tenure | 3.6yrs |
Board average tenure | 4.2yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -US$598m |
Mar 31 2024 | n/a | n/a | -US$601m |
Dec 31 2023 | US$1m | US$796k | -US$583m |
Sep 30 2023 | n/a | n/a | -US$458m |
Jun 30 2023 | n/a | n/a | -US$473m |
Mar 31 2023 | n/a | n/a | -US$430m |
Dec 31 2022 | US$4m | US$791k | -US$417m |
Sep 30 2022 | n/a | n/a | -US$400m |
Jun 30 2022 | n/a | n/a | -US$376m |
Mar 31 2022 | n/a | n/a | -US$370m |
Dec 31 2021 | US$29m | US$765k | -US$347m |
Sep 30 2021 | n/a | n/a | -US$323m |
Jun 30 2021 | n/a | n/a | -US$301m |
Mar 31 2021 | n/a | n/a | -US$264m |
Dec 31 2020 | US$843k | US$141k | -US$222m |
Compensation vs Market: Rich's total compensation ($USD1.16M) is below average for companies of similar size in the German market ($USD2.45M).
Compensation vs Earnings: Rich's compensation has been consistent with company performance over the past year.
CEO
Rich Adcock (55 yo)
4yrs
Tenure
US$1,156,903
Compensation
Mr. Richard Gerald Adcock, also known as Rich, has been the President of ImmunityBio, Inc. since March 05, 2021 and serves as its Director since March 29, 2021. He has been the Chief Executive Officer of I...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Executive Chairman of the Board and Global Chief Scientific & Medical Officer | 9.9yrs | US$865.34k | 41.8% € 1.5b | |
President | 4yrs | US$1.16m | 0.035% € 1.3m | |
Chief Financial Officer | 5.3yrs | US$1.06m | 0.027% € 965.1k | |
Chief Corporate Affairs Officer & Director | 3.6yrs | no data | 0.45% € 16.2m | |
Chief Operating Officer | 4.6yrs | no data | no data | |
Chief Accounting Officer | 2.9yrs | no data | 0.014% € 489.8k | |
Chief Technology Officer | 1.8yrs | no data | no data | |
General Counsel & Corporate Secretary | 3.3yrs | no data | no data | |
Chief Communications Officer & Head of Patient Advocacy | 4.6yrs | no data | no data | |
Chief Medical Officer | 4.2yrs | no data | no data | |
Chief Science Officer of Cellular | no data | no data | no data | |
Senior Vice President of Product Development & Vaccine Programs | 1.2yrs | no data | no data |
3.6yrs
Average Tenure
56yo
Average Age
Experienced Management: 26CA's management team is considered experienced (3.6 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Executive Chairman of the Board and Global Chief Scientific & Medical Officer | 9.9yrs | US$865.34k | 41.8% € 1.5b | |
President | 3.6yrs | US$1.16m | 0.035% € 1.3m | |
Chief Corporate Affairs Officer & Director | 17.8yrs | no data | 0.45% € 16.2m | |
Independent Director | 4.2yrs | US$470.00k | 0% € 0 | |
Independent Director | 3.7yrs | US$465.00k | 0.0011% € 41.6k | |
Independent Director | 9.3yrs | US$510.00k | 0.038% € 1.4m | |
Independent Director | 3.7yrs | US$472.50k | 0.0036% € 129.9k | |
Lead Independent Director | 5.3yrs | US$506.25k | 0.029% € 1.0m | |
Independent Director | 3.6yrs | US$487.50k | 0% € 0 |
4.2yrs
Average Tenure
68yo
Average Age
Experienced Board: 26CA's board of directors are considered experienced (4.2 years average tenure).